CD3G
ENSG00000160654
Target class
Unclassified protein
Chromosome
11
Approved drugs
10
Clinical candidates (approved and in development)
15
- Approved drugs
- 10
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- No
- Target name
- CD3G
- Gene name
- CD3 gamma subunit of T-cell receptor complex
- Gene symbol
- CD3G
- Protein name
- T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g)
- CD3-GAMMA
- CD3GAMMA
- Gene biotype
- Protein coding
- Gene family
- CD molecules
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 8.88
- Tissue specificity (Gini)
- 0.74
- Tissue specificity (tau)
- 0.945
- KEGG gene identifiers
- hsa:917
- Protein interaction confidence
- 0.836625
- Protein interaction partners
- 40
- R-HSA-198933
- R-HSA-202424
- R-HSA-202427
- R-HSA-202430
- R-HSA-202433
- R-HSA-2029481
- R-HSA-2029482
- R-HSA-2029485
- R-HSA-389948
- R-HSA-8856825
- R-HSA-8856828
- R-HSA-9664323
- R-HSA-9664422
- End position
- 118355161
- Start position
- 118344344
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein.
- Cytosol
- Plasma membrane
Publication evidence
- PubMed 8636209
- Tissue specificity (tau)
- 0.945436
- Expression inequality (Gini)
- 0.740033
Expression in transcripts per million
- Spleen
- 8.88
- Small Intestine - Terminal Ileum
- 5.31
- Whole Blood
- 5.03
- Lung
- 1.92
- Colon - Transverse
- 0.98
Expression in transcripts per million
- Spleen8.88
- Small Intestine - Terminal Ileum5.31
- Whole Blood5.03
- Lung1.92
- Colon - Transverse0.98
- Stomach0.97
- Bladder0.87
- Thyroid0.74
- Vagina0.72
- Fallopian Tube0.61
- Esophagus - Mucosa0.6
- Prostate0.59
- Cervix - Endocervix0.59
- Adipose - Visceral (Omentum)0.57
- Minor Salivary Gland0.55
- Adipose - Subcutaneous0.45
- Artery - Coronary0.42
- Cervix - Ectocervix0.41
- Testis0.35
- Uterus0.35
- Breast - Mammary Tissue0.32
- Artery - Aorta0.3
- Skin - Not Sun Exposed (Suprapubic)0.24
- Nerve - Tibial0.24
- Brain - Spinal cord (cervical c-1)0.2
And 29 more, listed on the interactive page.
- GO:0007163
- GO:0007166
- GO:0015031
- GO:0050852
- GO:0070228
- GO:0005886
- GO:0030669
- GO:0042105
- GO:0004888
- GO:0005515
- GO:0032395
- GO:0042802
Related records
Trials (624)
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Compassionate Use (CU) Program of Odronextamab
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
- A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
- A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Drugs (15)
- Blinatumomab T cell surface glycoprotein CD3 cross-linking agent
- Catumaxomab T cell surface glycoprotein CD3 cross-linking agent
- Elranatamab T cell surface glycoprotein CD3 binding agent
- Epcoritamab T cell surface glycoprotein CD3 binding agent
- FBT-A05 T cell surface glycoprotein CD3 cross-linking agent
- Flotetuzumab T cell surface glycoprotein CD3 binding agent
- Foralumab T cell surface glycoprotein CD3 inhibitor
- Glofitamab T cell surface glycoprotein CD3 binding agent
- Mosunetuzumab T cell surface glycoprotein CD3 binding agent
- Muromonab-CD3 T cell surface glycoprotein CD3 inhibitor
- Odronextamab T cell surface glycoprotein CD3 binding agent
- Solitomab T cell surface glycoprotein CD3 cross-linking agent
- Talquetamab T cell surface glycoprotein CD3 binding agent
- Tarlatamab T cell surface glycoprotein CD3 binding agent
- Teclistamab T cell surface glycoprotein CD3 binding agent